**Core tip:** To assess the diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index (APRI), and liver stiffness measurement (LSM) in patients with hepatitis B virus infection who have persistently normal alanine transaminase (PNALT), we enrolled 245 patients with chronic hepatitis B: 95 in PNALT group, 86 in intermittently elevated alanine transaminase (PIALT1) group \[alanine transaminase (ALT) within 1-2 × upper limit of normal value (ULN)\], and 64 in PIALT2 group (ALT \> 2 × ULN). The results showed that APRI and FIB-4 are not the ideal noninvasive hepatic fibrosis markers for PNALT patients. LSM is superior to APRI and FIB-4 in PNALT patients because of the influence of liver inflammation and necrosis.

INTRODUCTION
============

Approximately a third of the world's population have serological evidence of past or present hepatitis B virus (HBV) infection, and 350-400 million people are known to be chronic HBV surface antigen (HBsAg) carriers. The disease spectrum and natural history of chronic HBV infection are diverse and varied, ranging from an inactive carrier state to progressive chronic hepatitis B (CHB), which may progress to cirrhosis and hepatocellular carcinoma (HCC)\[[@B1],[@B2]\]. Chronic HBV infection is a dynamic process, and its natural history was schematically divided into ﬁve phases by the European Association for the Study of the Liver Clinical Practice Guidelines (2012) as follows\[[@B1]\]: (1) the "immune tolerant" phase; (2) the "immune reactive HBeAg-positive phase"; (3) the "inactive HBV carrier phase"; (4) "HBeAg-negative CHB" phase; and (5) the "HBeAg-negative CHB" or "HBsAg-negative" phase.

Although serum levels of alanine transaminase (ALT), an enzyme released from hepatocytes during liver injury, should reflect the degree of liver damage\[[@B3]\], not all patients with chronic HBV infection have persistently elevated ALT levels. Patients in the immune-tolerant phase and inactive carriers have persistently normal ALT (PNALT) levels\[[@B4],[@B5]\], while a proportion of patients with HBeAg-negative CHB may have intermittently normal ALT levels. Histological injury in patients with normal ALT levels has also been reported\[[@B5]-[@B10]\]. Furthermore, some large cohort studies have shown that patients with CHB who have normal serum ALT levels were also at risk for the development of cirrhosis and HCC\[[@B11],[@B12]\]. Liver biopsy (LB) is the current gold standard for assessing hepatic inﬂammation and ﬁbrosis in patients with chronic HBV infection who have PNALT\[[@B7]\]. The invasiveness of liver puncture, the limitation of the specimen, and the poor patient compliance have restricted the application of LB, which has led to the development of noninvasive methods such as FIB-4\[[@B13]\] and aspartate aminotransferase (AST)-to-platelet ratio index (APRI)\[[@B14]\] for evaluating fibrosis in patients with chronic HBV infection. Liver stiffness measurement (LSM) using transient elastography (FibroScan) has been widely used in the diagnosis of chronic liver fibrosis\[[@B15],[@B16]\]. However, the diagnostic value of FIB-4, APRI, and LSM in patients with HBV infection with PNALT is not clear.

In this study, we comprehensively evaluated the characteristics of histological abnormalities in a large population of Chinese CHB patients with PNALT, with an aim to analyze the diagnostic value of FIB-4, APRI, and LSM in patients with HBV who have PNALT.

MATERIALS AND METHODS
=====================

Ethics statement
----------------

The study was approved by the Medical Ethics Committee of The Third Hospital of Zhenjiang Affiliated Jiangsu University (No. 2013011), and written informed consent was obtained from each patient prior to participation. The study was conducted in accordance with the Declaration of Helsinki.

Patients
--------

This was a retrospective cohort study of patients with CHB diagnosed between January 2011 and June 2016 at the Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University. The patients were examined every 3 to 6 mo, or more often if clinically indicated. At each visit, liver biochemistry and HBV serology, including HBsAg, HBeAg, anti-HBe, and HBV DNA levels, and HBV genotype, were evaluated. The inclusion criteria were as follows\[[@B17]\]: (1) being HBsAg positive for at least 6 mo; (2) HBV DNA level \> 1000 copies/mL; and (3) patients with PNALT levels who had at least three ALT values taken in the year prior to baseline LB, with all values \> 40 IU/L and remaining so until the start of treatment or the last follow-up if not treated. Patients were categorized as having PIALT levels if they had at least three ALT values taken, and at least one measurement of \> 40 IU/L in the year prior to the baseline LB, or any time until the start of treatment or the last follow-up if not treated (intermittently elevated)\[[@B6]-[@B8],[@B10],[@B18],[@B19]\]. The exclusion criteria were as follows: (1) hepatitis A, C, or D, or human immunodeficiency virus coinfection; (2) evidence of liver disease with another etiology; (3) use of hepatotoxic drugs or regular consumption of alcohol; (4) previous antiviral (HBV) therapy or any liver functional protection therapy to alleviate hepatic inflammation; and (5) less than three normal ALT values taken prior to the biopsy. The clinical data from these participants were given new numbers and anonymized before analysis. All data were provided separately as Supporting Information.

Biochemical and serologic tests
-------------------------------

Biochemical tests and complete blood cell counts were performed using routine automated analyzers. The upper limit of normal value (ULN) of ALT level was 40 IU/L. HBsAg, HBeAg, and anti-HBe levels were assayed with commercially available enzyme-linked immunosorbent assay (ELISA) kits. HBV DNA level was measured using real-time polymerase chain reaction (PCR), with a lower detection limit of 1000 copies/mL (DaAn Gene Co, China).

Genotyping by multiplex PCR
---------------------------

Genotyping was performed using multiplex PCR with specific primers for each genotype (A-F) of HBV\[[@B20]\].

LB and histological assessment
------------------------------

Liver biopsies were obtained using a 16-G core aspiration needle, a biopsy length of at least 1.5 cm, and six portal tracts or more. Biopsies were fixed, paraffin-embedded, and stained with hematoxylin and eosin for morphological evaluation and Masson's trichrome stain for the assessment of fibrosis. The pathologist who reviewed all biopsy specimens was blinded to the biochemical and virological results of the patients, the amount of necrosis and inflammation, and the degree of fibrosis according to the Knodell scoring system\[[@B21]\]. Knodell necroinflammatory scores were classified into four categories as follows: Minimal (0-3), mild (4-6), moderate (7-9), and severe (10-14)\[[@B22]\]. Minimal and mild necroinflammatory scores were considered insignificant, while moderate and severe scores were considered significant. Knodell fibrosis scores were also classified into four categories as follows: Minimal (0), mild (1), moderate (2), and severe (3). Minimal and mild fibrosis scores were considered insignificant, while moderate and severe scores were considered significant.

LSM
---

LSM was assessed using transient elastography (FibroScan502, Echosens, Paris, France) with the 3.5-MHz standard probe by the same operator (experience, \> 10000 measurements) who was blinded to the other parameters of the patients, as previously described. The examination was performed with the patient lying in the dorsal decubitus position, with the right arm in maximal abduction. The tip of the probe transducer was placed on the skin, between the ribs at the level of the right lobe of the liver. The results are expressed in kPa, and each LSM corresponded to the median of 10 validated measurements.

Statistical analysis
--------------------

Results are presented as median (range) or mean ± SD as appropriate. Data on demographic and clinical features of the CHB patients were analyzed using Statistical Package for the Social Sciences (SPSS) version 21.0 (SPSS Inc, Chicago, IL, United States). Statistical analyses were performed using *χ*^2^ and Fisher exact tests for categorical variables. The Student's *t*-test or one-way analysis of variance was used for group comparisons of parametric quantitative data. The equations for the two noninvasive markers analyzed were as follows: FIB-4 = (Age × AST)/(PLT × ALT1/2) and APRI = (AST/ULN) × 100/PLT. The receiver-operating characteristic (ROC) curves were used to calculate the cutoff values of FIB-4, APRI, and LSM. The ROC analysis was performed using MedCalc software version 10.4.7.0 (MedCalc, Mariakerke, Belgium). All *P*-values were two-sided.

RESULTS
=======

Clinical and pathological characteristics of CHB patients with different levels of ALT
--------------------------------------------------------------------------------------

Table [1](#T1){ref-type="table"} shows that among 245 cases of CHB, 95 were in the PNALT group, 86 in the PIALT1 group (ALT within 1-2 × ULN), and 64 in the PIALT2 group (ALT \> 2 × ULN). Body mass index (BMI), platelet count (PLT), prothrombin activity (PTA), ALT and AST (aspiration aminotransferase), serum albumin, E antigen status (positive or negative), HBsAg level, and HBV DNA expression level (≥ 3, \< 5 and ≥ 5) were analyzed. We found that the differences in age, ALT, AST, PLT, and other factors were statistically significant (*P* \< 0.05) between the PNALT and PIALT groups. No significant differences were found in E antigen status, HBsAg level, and HBV DNA. The pathological examination revealed moderate inflammatory necrosis ratios of 16.81% (16/95), 32.56% (28/86), and 45.31% (28/64), and moderate liver fibrosis of 24.2% (23/95), 33.72% (29/86), and 43.75% (28/64) in the PNALT, PIALT1, and PIALT2 groups, respectively. The degrees of inflammation and liver fibrosis in the PIALT groups were significantly higher than those in the PNALT group (*P* \< 0.05).

###### 

Demographic and clinical characteristics of chronic hepatitis B patients *n* (%)

  **Characteristic**        **PNALT (*n* = 95)**   **PIALT1 (*n* = 86)**   **PIALT2 (*n* = 64)**   **Statistic**   ***P* value**
  ------------------------- ---------------------- ----------------------- ----------------------- --------------- ------------------------------------------
  Age (yr)                  34.5 ± 11.2            34.2 ± 12.5             36.5 ± 13.5             5.423           0.021[1](#T1FN1){ref-type="table-fn"}
  Sex                                                                                                              
  Male                      70 (73.7)              58 (67.4)               46 (71.9)               0.885           0.642[2](#T1FN2){ref-type="table-fn"}
  Female                    25 (26.3)              28 (32.6)               18 (28.1)                               
  BMI                       23.4 ± 2.65            24.0 ± 3.6              24.25 ± 3.37            1.231           0.543[1](#T1FN1){ref-type="table-fn"}
  PLT (× 10^9^/L)           200.1 ± 60.3           196.8 ± 65.4            186.5 ± 74.5            6.364           0.018[1](#T1FN1){ref-type="table-fn"}
  PTA (%)                   99.6 ± 6.7             99.6 ± 8.7              102.3 ± 10.3            0.674           0.774[1](#T1FN1){ref-type="table-fn"}
  ALB (g/L)                 41.3 ± 3.4             41.6 ± 3.7              42.4 ± 4.1              1.536           0.543[1](#T1FN1){ref-type="table-fn"}
  ALT (U/L)                 21.4 ± 4.3             56.2 ± 19.4             113.6 ± 55.3            25.754          \< 0.001[1](#T1FN1){ref-type="table-fn"}
  AST (U/L)                 22.6 ±6.8              55.4 ± 16.6             124.5 ± 57.6            31.644          \< 0.001[1](#T1FN1){ref-type="table-fn"}
  APRI                      0.32 ± 0.14            0.61 ± 0.44             1.25 ± 0.62             284.92          \< 0.001[1](#T1FN1){ref-type="table-fn"}
  FIB-4                     0.72 ± 0.36            1.12 ± 0.53             1.67 ± 0.84             56.37           \< 0.001[1](#T1FN1){ref-type="table-fn"}
  FibroScan (kPa)           5.33± 2.45             7.36 ± 3.14             10.22 ± 5.53            46.34           \< 0.001[1](#T1FN1){ref-type="table-fn"}
  HBsAg \[lg (IU/L)\]       4.41 ± 0.73            4.53 ± 0.88             4.38 ± 0.64             0.743           0.437
  HBV DNA \[lg (IU/mL)\]    6.78 ± 2.13            6.53 ± 2.43             6.42 ± 2.54             0.864           0.254[1](#T1FN1){ref-type="table-fn"}
  ≥ 3, \< 5                 15 (15.8)              11 (12.8)               10 (15.6)               0.384           0.825[2](#T1FN2){ref-type="table-fn"}
  ≥ 5                       80 (84.2)              75 (87.2)               54 (84.4)                               
  E antigen                                                                                                        
  Positive                  42 (44.2)              31 (36)                 29 (45.3)               1.78            0.411[2](#T1FN2){ref-type="table-fn"}
  Negative                  53 (55.8)              55 (64)                 35 (54.7)                               
  Necroinflammatory score   2.21 ± 2.14            3.47 ± 3.64             4.74 ± 3.65             23.43           0.001
  Minimal                   35 (32.4)              20 (23.3)               8 (12.5)                18.69           0.005
  Mild                      44 (38)                38 (44.2)               27 (42.4)                               
  Moderate                  15 (15.8)              26 (30.2)               22 (34.4)                               
  Severe                    1 (0.9)                2 (2.3)                 7 (10.9)                                
  Fibrosis score            1.53 ± 0.46            2.38 ± 1.27             2.85 ± 1.75             15.237          0.005[1](#T1FN1){ref-type="table-fn"}
  Minimal                   32 (33.7)              18 (20.9)               13 (20.3)               13.275          0.035[2](#T1FN2){ref-type="table-fn"}
  Mild                      40 (42.1)              40 (51.2)               23 (35.9)                               
  Moderate                  21 (22.1)              24 (27.9)               21 (32.8)                               
  Severe                    2 (2.1)                5 (5.8)                 7 (10.9)                                

One-way analysis of variance;

Pearson *χ*^2^. APRI = \[AST (U/L)/ULN × 100/PLT (10^9^/L)\]; FIB-4 = \[age (yr) × AST (U/L)\]/\[PLT (10^9^/L) × (ALT U/L)^1/2^\].

Diagnostic value of APRI in the three groups of CHB
---------------------------------------------------

We considered hepatic fibrosis (insignificant/significant) as a categorical variable and APRI as a variable to test the AUC of APRI in the PNALT, PIALT1, and PIALT2 groups and in all the patients. The AUC of APRI was 0.518 in the PNALT group (95%CI: 0.414-0.622; specificity, 43.1%; sensitivity, 69.6%; cutoff value, 0.202; *P* = 0.7852), 0.659 in the PNALT1 group (95%CI: 0.548-0.757; specificity, 34.5%; sensitivity, 82.4%; cutoff value, 0.524; *P* = 0.011), 0.735 in the PNALT2 group (95%CI: 0.609-0.837; specificity, 83.7%; sensitivity, 85.7%; cutoff value, 1.26; *P* \< 0.001), and 0.65 for all the patients (95%CI: 0.587-0.710; specificity, 88.5%; sensitivity, 54.4%; cutoff value, 1.15; *P* \< 0.001). APRI showed a high diagnostic value for hepatic fibrosis in CHB patients with abnormal ALT levels in comparison with those with normal ALT levels (Figure [1](#F1){ref-type="fig"}).

![Diagnostic value of aspartate aminotransferase-to-platelet ratio index in different groups of chronic hepatitis B patients. PNALT: Persistently normal alanine transaminase; APRI: Aspartate aminotransferase-to-platelet ratio index; AUC: Areas under the curve.](WJG-23-5746-g001){#F1}

Diagnostic value of FIB-4 in the three groups of CHB
----------------------------------------------------

We considered hepatic fibrosis (insignificant/significant) as a categorical variable and FIB-4 as a variable to test the AUC of FIB-4 in the PNALT, PIALT1, and PIALT2 groups and in all the patients. The AUC of FIB-4 was 0.597 in the PNALT group (95%CI: 0.492-0.697; specificity, 68.1%; sensitivity, 52.2%; cutoff value, 0.698; *P* = 0.152), 0.642 in the PNALT1 group (95%CI: 0.531-0.742; specificity, 67.9%; sensitivity, 56.9%; cutoff value, 1.174; *P* = 0.021), 0.667 in the PNALT2 group (95%CI: 0.538-0.780; specificity, 52.8%; sensitivity, 78.7%; cutoff value, 1.46; *P* = 0.015), and 0.659 for all the patients (95%CI: 0.596-0.718; specificity, 66.8%; sensitivity, 74.2%; cutoff value, 0.96; *P* \< 0.001). FIB-4 showed a high diagnostic value for hepatic fibrosis in CHB patients with abnormal ALT levels in comparison with those with normal ALT levels (Figure [2](#F2){ref-type="fig"}).

![Diagnostic value of FIB-4 in different groups of chronic hepatitis B patients. PNALT: Persistently normal alanine transaminase; AUC: Areas under the curve.](WJG-23-5746-g002){#F2}

Diagnostic value of LSM in the three groups of CHB
--------------------------------------------------

We considered hepatic fibrosis (insignificant/significant) as a categorical variable and LSM as a variable to test the AUC of LSM in the PNALT, PIALT1, and PIALT2 groups and in all the patients. The AUC of LSM was 0.769 in the PNALT group (95%CI: 0.009-0.879; 95%CI: 0.709-0.850; specificity, 79.2%; sensitivity, 70.1%; cutoff value, 7.3; *P* \< 0.001), 0.800 in the PNALT1 group (95%CI: 0.700-0.879; specificity, 72.4%; sensitivity, 82.7%; cutoff value, 7.5; *P* \< 0.001), 0.708 in the PNALT2 group (95%CI: 0.581-0.815; specificity, 72.7%; sensitivity, 67.9%; cutoff value, 8.5; *P* = 0.017), and 0.763 for all the patients (95%CI: 0.596-0.718; specificity, 78.2%; sensitivity, 70.1%; cutoff value, 7.5; *P* \< 0.001). LSM showed a high diagnostic value for the three groups of CHB, although the sensitivity and specificity in the PNALT2 showed a downward trend (Figure [3](#F3){ref-type="fig"}).

![Diagnostic value of liver stiffness measurement in different groups of chronic hepatitis B patients. PNALT: Persistently normal alanine transaminase; LSM: Liver stiffness measurement; AUC: Areas under the curve.](WJG-23-5746-g003){#F3}

Comparison of the diagnostic value of the three noninvasive liver fibrosis markers in CHB
-----------------------------------------------------------------------------------------

As shown in Table [2](#T2){ref-type="table"} and Figure [4](#F4){ref-type="fig"}, there was no significant difference in the AUCs between APRI and FIB-4 in the PNALT group; however, significant differences were found between APRI and LSM, and between FIB-4 and LSM in the PNALT group (*P* \< 0.05 for both). In the PIALT1 and PIALT2 groups, no significant difference (*P* \> 0.05) was found in AUCs for all comparisons (*P* \> 0.05 for all). In the overall patients, a significant difference in the AUCs was found only between LSM and APRI (*P* \< 0.05).

###### 

Pairwise comparisons of receiver-operating characteristic curves

                             **PNALT**         **PIALT1**         **PIALT2**        **All patients**
  -------------------------- ----------------- ------------------ ----------------- -------------------
  APRI *vs* FIB-4                                                                   
  Difference between areas   0.0628            0.0169             0.068             0.00904
  Standard error             0.0557            0.0699             0.0738            0.0245
  95%CI                      -0.046 to 0.172   -0.120 to 0.154    -0.077 to 0.213   -0.039 to 0.057
  *z* statistic              1.129             0.242              0.921             0.369
  *P* value                  0.2588            0.8087             0.3569            0.712
  APRI *vs* LSM                                                                     
  Difference between areas   0.256             0.124              0.0263            0.111
  Standard error             0.104             0.0896             0.0882            0.0518
  95%CI                      0.0525-0.459      -0.0511 to 0.30    -0.147 to 0.19    0.00909-0.212
  *z* statistic              2.465             1.389              0.298             2.135
  *P* value                  0.0137            0.1649             0.7655            0.0327
  FIB 4 *vs* LSM                                                                    
  Difference between areas   0.193             0.141              0.0417            0.102
  Standard error             0.106             0.0938             0.0957            0.0531
  95%CI                      -0.014 to 0.400   -0.0425 to 0.325   -0.146 to 0.229   -0.00246 to 0.206
  *z* statistic              1.829             1.507              0.435             1.914
  *P* value                  0.0374            0.1318             0.663             0.0557

![Comparison of the diagnostic value of the three noninvasive liver fibrosis markers in different groups of chronic hepatitis B patients. APRI: Aspartate aminotransferase-to-platelet ratio index; FIB-4: Fibrosis-4; LSM: Liver stiffness measurement.](WJG-23-5746-g004){#F4}

DISCUSSION
==========

Hepatic fibrosis is a compensatory repair process associated with inflammation and necrosis of the liver. Therefore, 25% to 40% of liver fibrosis cases will eventually progress to cirrhosis and even liver cancer. Early liver fibrosis can be reversed after correct treatment; thus, early diagnosis of liver fibrosis will be beneficial to the treatment of CHB.

LB is still the gold standard for assessment of liver fibrosis in CHB, although it is invasive, expensive, and associated with risk of complications and poor patient compliance, and of subjective differences in pathologists. The accuracy of the pathological diagnosis of liver fibrosis can only be approximately 90% and even reported to be \< 80%\[[@B23]\]. Therefore, noninvasive diagnostic markers for liver fibrosis have been developed, such as serum markers and models, imaging, transient liver hardness, and other noninvasive techniques. Although these noninvasive diagnostic methods have their own advantages and disadvantages, they have not completely replaced LB. However, new techniques and methods have become greatly improved. Among the noninvasive tests developed are FIB-4, APRI, and LSM; previous studies have shown these noninvasive markers and techniques to be strong predictors of liver fibrosis.

A multicenter, retrospective study reported that the AUCs of APRI were 0.72, 0.812, and 0.707 in CHB patients with F2, F3, and F4 fibrosis, respectively\[[@B24]\]. The AUCs of APRI were 0.65, 0.659, and 0.735 in our PNALT, PIALT1, and PIALT2 CHB patients, respectively. These results showed that the diagnostic value of APRI in the CHB patients with elevated ALT levels was better than that in the CHB patients with normal ALT. APRI is the ratio of AST to PLT, and elevated AST levels has a higher APRI value and thus is more likely to distinguish patient groups with different AST levels.

In a study of 388 cases of cirrhosis of varied severity assessed using APRI and FIB-4, the AUCs were 0.68 (95%CI: 0.63-0.74) and 0.73 (95%CI: 0.68-0.78)\[[@B25]\], respectively. In our study, the AUC of FIB-4 was 0.597 for PNALT, 0.642 for PNALT1, and 0.667 for PNALT2. The diagnostic value of FIB-4 in the CHB patients with elevated ALT levels was better than that in the CHB patients with normal ALT levels and APRI.

We detected LSM by FibroScan in the CHB patients, with an AUC of 0.769 for PNALT, 0.800 for PIALT1, 0.708 for PIALT2, and 0.763 for all the patients. LSM showed a good diagnostic value for the three groups of CHB patients. Furthermore, the diagnostic value of LSM in the high ALT group was not as good as that in the PNALT group, and the sensitivity and specificity in the PNALT2 group even had a downward trend. In a report on FibroScan in China\[[@B26]\], the AUCs were 0.916 and 0.971 for the diagnosis of ≥ F2 liver fibrosis (F0-1 *vs* F2-4) and cirrhosis (F = 4, F0-3 *vs* F4), and the sensitivity and accuracy in the ALT level ≥ 2 × ULN group were significantly lower than those in the other lower-level ALT groups. The reason is that LSM is susceptible to liver inflammation\[[@B27],[@B28]\] and cholestasis\[[@B29],[@B30]\].

We compared the three noninvasive methods for the diagnosis of hepatic fibrosis. The results showed that the AUC differences between LSM and APRI, and between LSM and FIB-4 were statistically significant in the PNALT group (*P* \< 0.05 for both), but not in the PIALT1 and PIALT2 groups (*P* \> 0.05 for all). For all the patients, we found that the AUC difference was statistically significant only between LSM and APRI (*P* \< 0.05).

In a previous report from South Korea, the diagnostic value of LSM for hepatic fibrosis was compared with that of APRI. The results suggested that LSM is superior to APRI in 916 patients with CHB (AUC: 0.774 *vs* 0.72 for ≥ F2, 0.849 *vs* 0.812 for ≥ F3, and 0.902 *vs* 0.707 for F4; all *P* \< 0.05)\[[@B24]\]. Another report revealed that LSM was better than APRI and FIB-4 when the LSM cutoff value was \> 13.6 kPa for the diagnosis of portal hypertension in cirrhosis patients\[[@B31]\].

In conclusion, we evaluated three common noninvasive hepatic fibrosis techniques in CHB patients with different ALT levels. The results showed that APRI and FIB-4 are not the ideal noninvasive hepatic fibrosis markers in the PNALT patients and that APRI and FIB-4 established according to the common blood biochemical indicators are more suitable for active CHB. LSM, which determines liver hardness for assessment of the degree of liver fibrosis, is superior to APRI and FIB-4 in patients with PNALT because of the influence of liver inflammation and necrosis.

COMMENTS
========

Background
----------

Although serum levels of alanine transaminase (ALT), an enzyme released from hepatocytes during liver injury, should reflect the degree of liver damage, not all patients with chronic HBV infection have persistently elevated ALT levels. Furthermore, some large cohort studies have shown that patients with chronic hepatitis B (CHB) who have normal serum ALT levels are also at risk for the development of cirrhosis and hepatocellular carcinoma. Liver biopsy is the current gold standard for assessing hepatic inﬂammation and ﬁbrosis in patients with chronic hepatitis B virus (HBV) who have persistently normal alanine transaminase (PNALT). The invasiveness of liver puncture, the limitation of the specimen, and the poor patient compliance have restricted the application of liver biopsy.

Research frontiers
------------------

The limitation of liver biopsy has led to the development of noninvasive methods such as FIB-4 and aspartate aminotransferase-to-platelet ratio index (APRI) for evaluating fibrosis in patients with chronic HBV infection. Liver stiffness measurement (LSM) using transient elastography (FibroScan) has been widely used in the diagnosis of chronic liver fibrosis. However, the diagnostic value of FIB-4, APRI, and LSM in patients with HBV infection with PNALT is not clear.

Innovations and breakthroughs
-----------------------------

The authors evaluated three common noninvasive hepatic fibrosis markers in CHB patients with different ALT levels. The results showed that APRI and FIB-4 are not the ideal noninvasive hepatic fibrosis markers for PNALT patients. LSM is superior to APRI and FIB-4 in PNALT patients because of the influence of liver inflammation and necrosis.

Applications
------------

Noninvasive markers such as FIB-4, APRI and liver stiffness measurement for evaluating fibrosis in patients with chronic HBV infection.

Terminology
-----------

PNALT means patients with hepatitis B virus infection who have persistently normal alanine transaminase.

Peer-review
-----------

The manuscript is well written and the numerical simulations are well performed.

Manuscript source: Unsolicited manuscript

Specialty type: Gastroenterology and hepatology

Country of origin: China

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

Institutional review board statement: The study was approved by the Medical Ethics Committee of the Third Hospital of Zhenjiang Affiliated Jiangsu University (No. 2013011).

Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.

Conflict-of-interest statement: All the authors have no conflict of interest related to the manuscript.

Data sharing statement: The original anonymous dataset is available on request from the corresponding author at tyw915\@sina.com.

Peer-review started: May 4, 2017

First decision: June 6, 2017

Article in press: July 12, 2017

P- Reviewer: Nakao T S- Editor: Qi Y L- Editor: Wang TQ E- Editor: Xu XR

[^1]: Author contributions: Tan YW and Zhou XB contributed equally to this work; Tan YW designed the research; Ye Y, He C and Ge GH collected and analysed the data, and drafted the manuscript; Zhou XB performed the research; Ye Y and He C interpreted the data and performed the statistical analysis; Tan YW revised the article; all authors have read and approved the final version to be published.

    Correspondence to: Dr. You-Wen Tan, Department of Hepatology, the Third Hospital of Zhenjiang Affiliated Jiangsu University, 300 Daijiamen, Zhenjiang 212001, Jiangsu Province, China. <tyw915@sina.com>

    Telephone: +86-511-88614915 Fax: +86-511-88970796
